March 5, 2021

Yescarta Receives Follicular Lymphoma Indication

March 5, 2021 – The U.S. FDA has approved a new indication for Yescarta® (axicabtagene ciloleucel), manufactured by Gilead, to treat relapsed or refractory follicular lymphoma (FL)
March 3, 2021

Azstarys Approved to Treat ADHD

March 3, 2021 – The U.S. FDA has approved AzstarysTM (serdexmethylphenidate/dexmethylphenidate), manufactured by Corium, to treat attention deficit hyperactivity disorder (ADHD) in